Regular Strength Acid Reducer, Ranitidine tablets, USP 75 mg, 160 tablets per bottle. [NDC: Brand] NDC CVS Health.: 69842-293-06
Perrigo Company PLC
CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine.
Prescription and over-the-counter medications
Perrigo Company PLC
CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine.
Presence of Foreign Tablets/Capsules: This is a spin-off recall of D-1581-2019 due to a product complaint where one of Lupin's Fenofibrate 145mg was observed in the 500 s count product bottle.
Perrigo Company PLC
CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine.
Perrigo Company PLC
CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine.
CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine.
CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine.
Strides Pharma Science Limited
Failed Tablet/Capsules Specifications: Oversized tablets were found in one lot of Potassium Chloride Tablets 750 mg.
Defective Delivery System: Out of specification for mechanical peel and shear.
Defective Delivery System: Out of specification for mechanical peel and shear.
Sun Pharmaceutical Industries
CGMP Deviations: Doxycycline capsules were not manufactured under Current Good Manufacturing Practice conditions.
CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine.
CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine.
Perrigo Company PLC
CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine.
CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine.
CGMP Deviations: During manufacturing Solifenacin Succinate Tablets might convert to Solifenacin Tartrate Tablets.
Perrigo Company PLC
CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine.
CGMP Deviations: During manufacturing Solifenacin Succinate Tablets might convert to Solifenacin Tartrate Tablets.
Marketed without an Approved NDA/ANDA: Product contains undeclared sildenafil which was discovered through FDA analysis.
Defective Delivery System: Out of specification for mechanical peel and shear.
Perrigo Company PLC
CGMP Deviation; Possible contamination with impurity N-nitrosodimethylamine.